A. Ahmad, Kristin M. Sanderson, D. Dickerson, N. Adda
{"title":"EDP-305(一种新型每日一次口服法内酯X受体激动剂)在健康受试者和假定患有非酒精性脂肪肝患者中的一期研究","authors":"A. Ahmad, Kristin M. Sanderson, D. Dickerson, N. Adda","doi":"10.11648/j.ijg.20210502.16","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":246347,"journal":{"name":"International Journal of Gastroenterology","volume":"50 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease\",\"authors\":\"A. Ahmad, Kristin M. Sanderson, D. Dickerson, N. Adda\",\"doi\":\"10.11648/j.ijg.20210502.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":246347,\"journal\":{\"name\":\"International Journal of Gastroenterology\",\"volume\":\"50 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11648/j.ijg.20210502.16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/j.ijg.20210502.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease